June 2, 2025
Source: drugdu
97
On May 29, GENOR Bio (06998) issued an announcement that the China National Medical Products Administration has approved the new drug application for Leloxili (GB491).
Leroxili (GB491) is a novel, highly potent and selective oral cyclin-dependent kinase 4 and 6 inhibitor co-developed with G1 Therapeutics Inc., designed to improve the treatment of patients with advanced breast cancer. The drug is indicated for adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, and can be used in combination with aromatase inhibitors as initial endocrine therapy, or in combination with fulvestrant for patients whose disease has progressed after previous endocrine therapy.
https://finance.eastmoney.com/a/202505293417987240.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.